Cancer treatment
-
Lixte’s Big Bet: Making Other Cancer Drugs Work Harder
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a Nasdaq-listed biotech with an unusually focused story: one main drug,…
-
Coeptis Therapeutics’ Dave Mehalick on Making Cell Therapy Universally Accessible
April 30, 2024 — In a recent interview with InvestorNews, Dave Mehalick, Chairman, President, and CEO of Coeptis…
-
Dr. Colleen Delaney from Coeptis Therapeutics on the development of next-generation cell therapy technologies for cancer and infectious diseases
In a recent Investor.Coffee interview with host Jack Lifton, Dr. Colleen Delaney, Chief Scientific and Medical Officer at…
-
Coeptis CEO Dave Mehalick on NASDAQ listing and entering the Cancer Treatment Race
Innovative cell therapy platforms have the potential to disrupt conventional cancer treatment In an InvestorCoffee interview with host…
-
Promising Advancements in Gene Therapy are Leading to Potential Investment Opportunities
Today’s discussion is about a topic that fascinates me even though I can say that I do not…
-
David Regan of Sona Nanotech provides an update on its agreement with Siva Therapeutics to develop cancer treating therapies
In this InvestorIntel interview, Sona Nanotech Inc.’s (CSE: SONA | OTCQB: SNANF) CEO David Regan provides Tracy Weslosky with…
-
Focused on a better future, Siva’s cancer tumor therapy system selects Sona’s gold nanorod for delivery
Today we are going to talk about a company that is making progress in the targeted treatment of…
-
Dr. Charles Meakin on the benefits of StageZero Life Sciences early diagnostic cancer test
In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Charles Meakin, Chief Medical Officer at CareOncology.com on…
